2Papanas N, Maltezos E. Oral antidiabetic agents: anti- atherosclemtic properties beyond glucose lowering? [J]Curr PharmDes, 2009, 15(27): 3179.
3Small DS, Farid NA, Payne CD, et al. Effects of the proton pump inhibitor lansoprazol,e on the pharmacokinetics and pharmacodynamics of prasugrel and clopidogre [ J ]. J Clin Pharmacol, 2008, 48: 475.
4Puri R,Worthley MI,Nicholls SJ. Intravascular imaging of vulnerable coronary plaque: current and future concepts[J]. Nat Rev Cardiol,2011,8(3):131-9.
5Patti G,Chello M,Gatto Let al. Short-term atorvastatin preload reduces levels of adhesion molecules in patients with acute coronary syndrome undergoing pereutaneous coronary intervention. Results from the ARMYDA-ACS CAMs (Atorvastatin for Reduction of MYocardial Damage during Angioplasty-Cell Adhesion Molecules) substudv[J]. J Cardiovase Med (Ha~erstown) 2010,11 (11):795-800.
6Nusca A,Melfi R,Di Sciascio G. Percutaneous coronary interventions and statins therapy[J]. Ther Adv Cardiovasc Dis,2008,2(2): 101-7.
8Hong YJ,Jeong MH,Choi YH,et al. Relation between high-sensitivity C-reactive protein and coronary plaque components in patients with acute coronary syndrome: virtual histology-intravascular ultrasound analysis[J]. Korean Circ J,2011,41(8):440-6.
9Ohbuchi M,Noguchi K,Kawamura A,et al. Different effects of proton pump inhibitors and famotidine on the clopidogrel metabolic activation by recombinant CYP2B6, CYP2C19 and CYP3A4[J]. Xenobiotica,2012,42(7):633-40.
10Vane J R,Bakhle Y S,Botting R M. Cyclooxygenase[J].Ann Rev PharmacolToxicol,1998.97-120.
